Company attributes
Other attributes
GlycoT Therapeutics is a company that aims to apply its innovative and proprietary chemoenzymatic glycosylation technology to glycoengineering of therapeutic proteins such as monoclonal antibodies, to enhance its therapeutic efficacy.
The company applies its technology to the production of enzymes, oligosaccharides, glycopeptides, and other glycoprotein products as valuable research tools for disease diagnosis and glycobiology research field.
The key technology of GlycoT that was developed by Prof. Wang’s group in University of Maryland permits chemoenzymatic glycoengineering of therapeutic antibodies and other glycoprotein products to deliver structurally well-defined, homogeneous glycoforms with unique properties. This technology development has brought about more than a dozen of US patent applications, including 6 issued US patents and 4 international patents.
